Comparative Pharmacology
Head-to-head clinical analysis: TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis; electrolytes maintain acid-base balance and cellular function; dextrose provides caloric energy. Sulfite-free formulation reduces risk of allergic reactions.
Total parenteral nutrition (TPN) solution providing essential amino acids, electrolytes, and dextrose. Dextrose supplies calories to spare protein catabolism; amino acids support protein synthesis; electrolytes maintain acid-base and fluid balance.
Intravenous infusion; dose determined by individual protein and caloric requirements, typically 1.5 to 2.5 g/kg/day of amino acids (equivalent to 35-59 mL/kg/day of TRAVASOL 4.25%) for adults.
Intravenous administration of 1.5-2.5 L/day in divided doses, adjusted based on metabolic needs, fluid status, and electrolytes. Typical rate: 100-200 mL/hour via central line.
None Documented
None Documented
Amino acids: 0.5-2 hours; dextrose: 1-2 hours; clinical context: rapid elimination necessitates continuous infusion to maintain nutrient levels.
Not applicable as a single entity; components have various half-lives. Glucose has a plasma half-life of approximately 1.5-2 hours. Amino acids have variable half-lives (minutes to hours). Clinical context: continuous infusion maintains steady state.
Renal excretion of amino acids and dextrose metabolites; virtually 100% renal elimination of infused water and electrolytes.
Amino acids and dextrose are metabolized; excess nitrogen is excreted as urea via renal route (approximately 90% of nitrogen output). Electrolytes are excreted renally. Biliary/fecal elimination is minimal (<5%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution